New immunotherapy cocktail targets recurrent brain tumors
NCT ID NCT04656535
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 29 times
Summary
This early-phase study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in people whose glioblastoma has come back after initial treatment. The goal is to see if the drugs are safe and can boost the immune system to fight the tumor. About 46 participants will receive the drugs before surgery, allowing researchers to study how the treatment affects the tumor and its surroundings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
Yale University
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.